Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

The Continually Improving HCV Treatment Landscape

Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Of the approximately 3 mill...

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Of the approximately 3 million persons living with HCV infection in the United States, an estimated 38% are linked to care, 11% are treated, and 6% achieve cure. Recent development of highly effective and well-tolerated direct acting antiviral (DAA) therapy to treat the infection shows promise in reducing HCV-related morbidity and mortality, with the potential to cure in more than 95% of patients. However, lack of provider expertise in HCV treatment and limited access to specialists are well-documented barriers. In this CME activity, Dr. Michael Fried will review current treatment options for HCV and discuss the expanding role of the primary care provider. He will also describe ways to provide evidence-based care that optimize outcomes for patients with HCV.

    Click here to view additional topics related to this special series on infectious diseases.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.

    The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

    Faculty and Planners report the following relationship(s):
    Michael W. Fried, MD
    Consulting Fees: AbbVie, BMS, Gilead, Merck
    Contracted Research: Abbvie, BMS, Gilead, Merck, NIH.
    Ownership Stock: TARGET PharmaSolutions

    External Reviewer reports the following relationship(s):
    Rebecca Clark, MD
    No relevant financial relationships to disclose.

    Vindico Medical Education staff report the following relationship(s):

    No relevant financial relationships to disclose.

    Interviewer Carlene A. Muto, MD, MS, was not involved in the development of the CME content for this activity. The interview questions were written by Dr. Muto and Vindico. Dr. Muto reports the following relationships:
    No relevant financial relationships to disclose.

    Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

  • Target Audience

    The intended audience for one or more interviews in the series is primary care physicians, family physicians/general practitioners, internal medicine physicians, infectious disease specialists, gastroenterologists/hepatologists and other health care professionals involved in the care of patients with hepatitis C.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:
    • Review strategies for appropriate patient monitoring for treatment response and adverse reactions in patients undergoing HCV therapy.
    • Apply knowledge of the clinical safety, efficacy, and recommended usage of new and emerging agents to the treatment of patients with HCV.

  • Accreditation and Credit Designation Statements

    This continuing medical education activity is provided by Vindico Medical Education.

    Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This enduring material is approved for 1 year from the date of original release, May 13, 2016 to May 12, 2017.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

  • Terms of Use

    Unlabeled and Investigational Usage:
    The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

  • Instructions

    To participate in this CME activity, you must read the objectives, answer the pretest question, view content, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate for immediate download on

  • Disclaimer

    Copyright & Disclaimer Statement: 
    Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    CME Questions?
    Contact us at

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.